Key Takeaways
- • The British Business Bank commits up to £46 million (€53.6 million) to Zinc Capital Management's Science-for-Impact Fund, its second institutional fund focused on deep technology investment.
- • The Science-for-Impact Fund targets a total close of £70 million and aims to build a portfolio of approximately 80 UK-based deep tech startups operating in health and climate sectors.
- • This public sector backing represents a significant capital injection into the UK deep tech ecosystem, positioning Zinc as one of the country's most active venture investors in science-driven companies emerging from research institutions.
- • The fund targets companies commercializing laboratory research and scientific breakthroughs, addressing a critical gap in early-stage funding for pre-revenue deep tech ventures with long development timelines.
Summary
The British Business Bank has committed up to £46 million to Zinc Capital Management's second institutional fund, the Science-for-Impact Fund, according to announcements made on 2 September 2026. This public sector commitment represents a substantial endorsement of Zinc's investment thesis and provides meaningful capital toward the fund's £70 million target close. The deployment of public capital through the British Business Bank underscores government support for early-stage deep technology commercialization in the UK innovation economy.
The Science-for-Impact Fund is structured to deploy capital across a diversified portfolio of approximately 80 UK-based deep tech startups, with particular focus on companies developing solutions in health and climate sectors. This portfolio approach reflects a systematic strategy to identify and support emerging ventures at the stage where they are transitioning scientific discoveries from laboratory environments into commercially viable products and services. The £70 million fund size suggests an average deployment per company in the region of £875,000, typical for seed-to-Series A stage deep tech investments.
Zinc Capital Management's receipt of this public backing positions the firm as a central player in the UK's deep tech venture ecosystem. The British Business Bank's decision to commit capital to Zinc's second fund indicates confidence in the firm's investment thesis, operational execution, and portfolio performance from its prior vehicle. This commitment reflects broader policy recognition that deep technology ventures—characterized by long development timelines, high capital requirements, and significant scientific risk—require dedicated institutional capital sources distinct from traditional venture funding.
The fund's health and climate focus aligns with broader UK innovation policy priorities and addresses significant market gaps in funding for breakthrough technologies that may take years to commercialize. Companies in these sectors often face extended pre-revenue phases and require patient capital willing to absorb extended development cycles before achieving material revenue or profitability milestones.
The Science-for-Impact Fund is structured to deploy capital across a diversified portfolio of approximately 80 UK-based deep tech startups, with particular focus on companies developing solutions in health and climate sectors. This portfolio approach reflects a systematic strategy to identify and support emerging ventures at the stage where they are transitioning scientific discoveries from laboratory environments into commercially viable products and services. The £70 million fund size suggests an average deployment per company in the region of £875,000, typical for seed-to-Series A stage deep tech investments.
Zinc Capital Management's receipt of this public backing positions the firm as a central player in the UK's deep tech venture ecosystem. The British Business Bank's decision to commit capital to Zinc's second fund indicates confidence in the firm's investment thesis, operational execution, and portfolio performance from its prior vehicle. This commitment reflects broader policy recognition that deep technology ventures—characterized by long development timelines, high capital requirements, and significant scientific risk—require dedicated institutional capital sources distinct from traditional venture funding.
The fund's health and climate focus aligns with broader UK innovation policy priorities and addresses significant market gaps in funding for breakthrough technologies that may take years to commercialize. Companies in these sectors often face extended pre-revenue phases and require patient capital willing to absorb extended development cycles before achieving material revenue or profitability milestones.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.